_id
690daa06ccc777a4e85d0893
Ticker
ADVB
Name
Advanced Biomed Inc. Common Stock
Exchange
NASDAQ
Address
122 East 42nd Street, New York, NY, United States, 10168
Country
USA
Sector
Healthcare
Industry
Diagnostics & Research
Currency
USD
Website
https://www.advanbiomed.com
Description
Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies for precision oncology detection, diagnosis, and treatment in Taiwan. Its devices include A+Pre, an automated sample preparation system that enables pre-concentration of diluted blood samples; AC-1000, a rare cell device to solve the problem of detection of hypercoagulable state samples of tumor patients; A+SCDrop, a circulating tumor cell (CTC) single-cell capture device; and A+CellScan, an analyzer with an immunostaining chip for immunostaining/analysis of the AC-1000 product. The company also offers microfluidic biochips, such as A+Pre, AC-1000 CTC enrichment, and A+CellScan chips to provide assay products and services to cancer patients. In addition, its immunochromogenic kits include A+CTCE kit to identify epithelial circulating tumor cells and determined by the immunochromogenicity of EpCAM, CK (pan), CD45, and CD14 antibodies; A+CTCM kit to identify mesenchymal circulating tumor cells based on the immunochromogenicity of Vimentin, CD45, and CD14 antibodies; A+EMT to identify epithelial-to-mesenchymal circulating tumor cells determined by the immunochromogenicity of cell-surface Vimentin, and CD45 and CD14 antibodies; and A+CM to identify tumor-associated macrophages based on the immunochromogenicity of PD-L1, CD45, and CD14 antibodies. Further, the company is developing A+LCGuard for early screening of lung cancer. Additionally, it establishes and operates medical clinics in the People's Republic of China. The company was founded in 2014 and is headquartered in New York, New York.
Last Close
0.2941
Volume
14928
Current Price
0.296
Change
-0.0207
Last Updated
2026-01-20T14:45:43.676Z
Image
data:image/webp;base64,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
Ipo Date
2025-03-06T00:00:00.000Z
Market Cap
6405440
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.978
Sentiment Sources
2
Current Quarter
2025-09-30
Revenue
17200
Cost Of Revenue
1603
Gross Profit
-1603
Operating Expenses
15900
Operating Income
-17503
Interest Expense
-
Pretax Income
-12925
Net Income
-12925
Eps
-0.0005972735674676525
Dividends Per Share
-
Shares Outstanding
21640000
Income Tax Expense
-
EBITDA
-11325
Operating Margin
-101.76162790697674
Total Other Income Expense Net
4577
Cash
2656519
Short Term Investments
-
Receivables
10044
Inventories
9296
Total Current Assets
5844133
Property Plant Equipment
42797
Total Assets
6242970
Payables
21050
Short Term Debt
49477
Long Term Debt
-
Total Liabilities
3238846
Equity
3004124
Bs_currency_symbol
USD
Depreciation
47992
Change In Working Capital
-9070
Cash From Operations
-20390
Capital Expenditures
59.15
Cash From Investing
-59.17
Cash From Financing
14949
Net Change In Cash
-12247
Cf_currency_symbol
USD
PE
-
PB
2.1322155809813443
ROE
-0.43024189414285163
ROA
-0.2070328705728203
FCF
-20449.15
Fcf Percent
-1.188904069767442
Piotroski FScore
0
Health Score
24
Deep Value Investing Score
3
Defensive Investing Score
6
Dividend Investing Score
1.5
Economic Moat Investing Score
3.3
Garp Investing Score
1
Growth Investing Score
0.5
Momentum Investing Score
2.5
Net Net Investing Score
3
Quality Investing Score
2
Value Investing Score
3.5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
17200
Quarters > 0 > income Statement > cost Of Revenue
1603
Quarters > 0 > income Statement > gross Profit
-1603
Quarters > 0 > income Statement > operating Expenses
15900
Quarters > 0 > income Statement > operating Income
-17503
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
-12925
Quarters > 0 > income Statement > net Income
-12925
Quarters > 0 > income Statement > eps
-0.0005972735674676525
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
21640000
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-11325
Quarters > 0 > income Statement > operating Margin
-101.76162790697674
Quarters > 0 > income Statement > total Other Income Expense Net
4577
Quarters > 0 > income Statement > currency_symbol
USD
Quarters > 0 > balance Sheet > cash
2656519
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
10044
Quarters > 0 > balance Sheet > inventories
9296
Quarters > 0 > balance Sheet > total Current Assets
5844133
Quarters > 0 > balance Sheet > property Plant Equipment
42797
Quarters > 0 > balance Sheet > total Assets
6242970
Quarters > 0 > balance Sheet > payables
21050
Quarters > 0 > balance Sheet > short Term Debt
49477
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
3238846
Quarters > 0 > balance Sheet > equity
3004124
Quarters > 0 > balance Sheet > currency_symbol
USD
Quarters > 0 > cash Flow > net Income
-386901
Quarters > 0 > cash Flow > depreciation
47992
Quarters > 0 > cash Flow > change In Working Capital
-9070
Quarters > 0 > cash Flow > cash From Operations
-20390
Quarters > 0 > cash Flow > capital Expenditures
59.15
Quarters > 0 > cash Flow > cash From Investing
-59.17
Quarters > 0 > cash Flow > cash From Financing
14949
Quarters > 0 > cash Flow > net Change In Cash
-12247
Quarters > 0 > cash Flow > currency_symbol
USD
Quarters > 0 > ratios > PE
-0.0005972735674676525
Quarters > 0 > ratios > PB
2.1322155809813443
Quarters > 0 > ratios > ROE
-0.43024189414285163
Quarters > 0 > ratios > ROA
-0.2070328705728203
Quarters > 0 > ratios > FCF
-20449.15
Quarters > 0 > ratios > Piotroski FScore
0
Quarters > 0 > ratios > fcf Percent
-1.188904069767442
Quarters > 0 > health Score
24
Quarters > 1 > quarter
2025-03-31
Quarters > 1 > income Statement > revenue
0
Quarters > 1 > income Statement > cost Of Revenue
2375
Quarters > 1 > income Statement > gross Profit
-2375
Quarters > 1 > income Statement > operating Expenses
20814
Quarters > 1 > income Statement > operating Income
-23190
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
-42075
Quarters > 1 > income Statement > net Income
-42075
Quarters > 1 > income Statement > eps
-0.00210375
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
20000000
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-39694
Quarters > 1 > income Statement > operating Margin
-
Quarters > 1 > income Statement > total Other Income Expense Net
-18884
Quarters > 1 > income Statement > currency_symbol
USD
Quarters > 1 > balance Sheet > cash
156135
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
6474
Quarters > 1 > balance Sheet > inventories
-7805
Quarters > 1 > balance Sheet > total Current Assets
7731148
Quarters > 1 > balance Sheet > property Plant Equipment
180851
Quarters > 1 > balance Sheet > total Assets
8287598
Quarters > 1 > balance Sheet > payables
3974986
Quarters > 1 > balance Sheet > short Term Debt
142524
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
4157815
Quarters > 1 > balance Sheet > equity
4129783
Quarters > 1 > balance Sheet > currency_symbol
USD
Quarters > 1 > cash Flow > net Income
-42075
Quarters > 1 > cash Flow > depreciation
2375
Quarters > 1 > cash Flow > change In Working Capital
-64025
Quarters > 1 > cash Flow > cash From Operations
-3409572
Quarters > 1 > cash Flow > capital Expenditures
2215
Quarters > 1 > cash Flow > cash From Investing
-2215
Quarters > 1 > cash Flow > cash From Financing
5898956
Quarters > 1 > cash Flow > net Change In Cash
2526865
Quarters > 1 > cash Flow > currency_symbol
USD
Quarters > 1 > ratios > PE
-0.00210375
Quarters > 1 > ratios > PB
1.4334893625161418
Quarters > 1 > ratios > ROE
-1.0188186643220722
Quarters > 1 > ratios > ROA
-0.5076863042826161
Quarters > 1 > ratios > FCF
-3411787
Quarters > 1 > ratios > Piotroski FScore
0
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
32
Quarters > 2 > quarter
2024-12-31
Quarters > 2 > income Statement > revenue
0
Quarters > 2 > income Statement > cost Of Revenue
-
Quarters > 2 > income Statement > gross Profit
-
Quarters > 2 > income Statement > operating Expenses
525729
Quarters > 2 > income Statement > operating Income
-525729
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
-907904
Quarters > 2 > income Statement > net Income
-907904
Quarters > 2 > income Statement > eps
-0.04195489833641405
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
21640000
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-
Quarters > 2 > income Statement > operating Margin
-
Quarters > 2 > income Statement > total Other Income Expense Net
-397592
Quarters > 2 > income Statement > currency_symbol
USD
Quarters > 2 > balance Sheet > cash
2657235
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
-
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
3138891
Quarters > 2 > balance Sheet > property Plant Equipment
642274
Quarters > 2 > balance Sheet > total Assets
4504152
Quarters > 2 > balance Sheet > payables
617865
Quarters > 2 > balance Sheet > short Term Debt
-
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
3885120
Quarters > 2 > balance Sheet > equity
619032
Quarters > 2 > balance Sheet > currency_symbol
USD
Quarters > 2 > cash Flow > net Income
-907904
Quarters > 2 > cash Flow > depreciation
99071
Quarters > 2 > cash Flow > change In Working Capital
-33008
Quarters > 2 > cash Flow > cash From Operations
-841841
Quarters > 2 > cash Flow > capital Expenditures
0
Quarters > 2 > cash Flow > cash From Investing
-
Quarters > 2 > cash Flow > cash From Financing
408286
Quarters > 2 > cash Flow > net Change In Cash
10243
Quarters > 2 > cash Flow > currency_symbol
USD
Quarters > 2 > ratios > PE
-0.04195489833641405
Quarters > 2 > ratios > PB
10.347510306413884
Quarters > 2 > ratios > ROE
-146.66511585830781
Quarters > 2 > ratios > ROA
-20.157046209808193
Quarters > 2 > ratios > FCF
-841841
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-
Quarters > 2 > health Score
17
Quarters > 3 > quarter
2024-09-30
Quarters > 3 > income Statement > revenue
0
Quarters > 3 > income Statement > cost Of Revenue
3162
Quarters > 3 > income Statement > gross Profit
-3162
Quarters > 3 > income Statement > operating Expenses
12926
Quarters > 3 > income Statement > operating Income
-16088
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-8216
Quarters > 3 > income Statement > net Income
-8216
Quarters > 3 > income Statement > eps
-0.0004108
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
20000000
Quarters > 3 > income Statement > income Tax Expense
-
Quarters > 3 > income Statement > EBITDA
-5056
Quarters > 3 > income Statement > operating Margin
-
Quarters > 3 > income Statement > total Other Income Expense Net
7872
Quarters > 3 > income Statement > currency_symbol
USD
Quarters > 3 > balance Sheet > cash
2646992
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
7929
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
3132736
Quarters > 3 > balance Sheet > property Plant Equipment
601294
Quarters > 3 > balance Sheet > total Assets
4473771
Quarters > 3 > balance Sheet > payables
641955
Quarters > 3 > balance Sheet > short Term Debt
1253444
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
3379941
Quarters > 3 > balance Sheet > equity
1093830
Quarters > 3 > balance Sheet > currency_symbol
USD
Quarters > 3 > cash Flow > net Income
-265580
Quarters > 3 > cash Flow > depreciation
102218
Quarters > 3 > cash Flow > change In Working Capital
133682
Quarters > 3 > cash Flow > cash From Operations
-29680
Quarters > 3 > cash Flow > capital Expenditures
19978
Quarters > 3 > cash Flow > cash From Investing
-19978
Quarters > 3 > cash Flow > cash From Financing
392525
Quarters > 3 > cash Flow > net Change In Cash
39019
Quarters > 3 > cash Flow > currency_symbol
USD
Quarters > 3 > ratios > PE
-0.0004108
Quarters > 3 > ratios > PB
5.41217556658713
Quarters > 3 > ratios > ROE
-0.7511222036331057
Quarters > 3 > ratios > ROA
-0.1836482019307649
Quarters > 3 > ratios > FCF
-49658
Quarters > 3 > ratios > Piotroski FScore
0
Quarters > 3 > ratios > fcf Percent
-
Quarters > 3 > health Score
19
Annuals > 0 > quarter
2025-06-30
Annuals > 0 > income Statement > revenue
-
Annuals > 0 > income Statement > cost Of Revenue
10711
Annuals > 0 > income Statement > gross Profit
-10711
Annuals > 0 > income Statement > operating Expenses
83401
Annuals > 0 > income Statement > operating Income
-94112
Annuals > 0 > income Statement > interest Expense
-
Annuals > 0 > income Statement > pretax Income
-101524
Annuals > 0 > income Statement > net Income
-101524
Annuals > 0 > income Statement > eps
-0.0046914972273567465
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
21640000
Annuals > 0 > income Statement > income Tax Expense
-
Annuals > 0 > income Statement > EBITDA
-90815
Annuals > 0 > income Statement > operating Margin
-
Annuals > 0 > income Statement > total Other Income Expense Net
-7412
Annuals > 0 > income Statement > currency_symbol
USD
Annuals > 0 > balance Sheet > cash
2903915000
Annuals > 0 > balance Sheet > short Term Investments
-
Annuals > 0 > balance Sheet > receivables
7956
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
6032571000
Annuals > 0 > balance Sheet > property Plant Equipment
65399000
Annuals > 0 > balance Sheet > total Assets
6512343000
Annuals > 0 > balance Sheet > payables
21658
Annuals > 0 > balance Sheet > short Term Debt
1119178
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
3034779000
Annuals > 0 > balance Sheet > equity
3477564000
Annuals > 0 > balance Sheet > currency_symbol
-
Annuals > 0 > cash Flow > net Income
-101524
Annuals > 0 > cash Flow > depreciation
10711
Annuals > 0 > cash Flow > change In Working Capital
-90650
Annuals > 0 > cash Flow > cash From Operations
-181464
Annuals > 0 > cash Flow > capital Expenditures
985
Annuals > 0 > cash Flow > cash From Investing
-985
Annuals > 0 > cash Flow > cash From Financing
184867
Annuals > 0 > cash Flow > net Change In Cash
19018
Annuals > 0 > cash Flow > currency_symbol
-
Annuals > 0 > ratios > PE
-0.0046914972273567465
Annuals > 0 > ratios > PB
0.0018419330312828175
Annuals > 0 > ratios > ROE
-0.00291939990177032
Annuals > 0 > ratios > ROA
-0.001558947371168871
Annuals > 0 > ratios > FCF
-182449
Annuals > 0 > ratios > Piotroski FScore
1
Annuals > 0 > ratios > fcf Percent
-
Annuals > 0 > health Score
38
Annuals > 1 > quarter
2024-06-30
Annuals > 1 > income Statement > revenue
0
Annuals > 1 > income Statement > cost Of Revenue
12550
Annuals > 1 > income Statement > gross Profit
-12550
Annuals > 1 > income Statement > operating Expenses
67276
Annuals > 1 > income Statement > operating Income
-79827
Annuals > 1 > income Statement > interest Expense
-
Annuals > 1 > income Statement > pretax Income
-87387
Annuals > 1 > income Statement > net Income
-87387
Annuals > 1 > income Statement > eps
-0.00436935
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
20000000
Annuals > 1 > income Statement > income Tax Expense
-
Annuals > 1 > income Statement > EBITDA
-74836
Annuals > 1 > income Statement > operating Margin
-
Annuals > 1 > income Statement > total Other Income Expense Net
-7560
Annuals > 1 > income Statement > currency_symbol
USD
Annuals > 1 > balance Sheet > cash
2607973
Annuals > 1 > balance Sheet > short Term Investments
-
Annuals > 1 > balance Sheet > receivables
6324
Annuals > 1 > balance Sheet > inventories
-6324
Annuals > 1 > balance Sheet > total Current Assets
3051110
Annuals > 1 > balance Sheet > property Plant Equipment
651269
Annuals > 1 > balance Sheet > total Assets
4460247
Annuals > 1 > balance Sheet > payables
620476
Annuals > 1 > balance Sheet > short Term Debt
64128
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
2796989
Annuals > 1 > balance Sheet > equity
1663258
Annuals > 1 > balance Sheet > currency_symbol
USD
Annuals > 1 > cash Flow > net Income
-2782278
Annuals > 1 > cash Flow > depreciation
399602
Annuals > 1 > cash Flow > change In Working Capital
256336
Annuals > 1 > cash Flow > cash From Operations
-2126340
Annuals > 1 > cash Flow > capital Expenditures
74110
Annuals > 1 > cash Flow > cash From Investing
-74110
Annuals > 1 > cash Flow > cash From Financing
1866820
Annuals > 1 > cash Flow > net Change In Cash
-14306
Annuals > 1 > cash Flow > currency_symbol
USD
Annuals > 1 > ratios > PE
-0.00436935
Annuals > 1 > ratios > PB
3.5592794383072257
Annuals > 1 > ratios > ROE
-5.253965410056647
Annuals > 1 > ratios > ROA
-1.9592412707188638
Annuals > 1 > ratios > FCF
-2200450
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-
Annuals > 1 > health Score
19
Annuals > 2 > quarter
2023-06-30
Annuals > 2 > income Statement > revenue
0
Annuals > 2 > income Statement > cost Of Revenue
11888
Annuals > 2 > income Statement > gross Profit
-11888
Annuals > 2 > income Statement > operating Expenses
88083
Annuals > 2 > income Statement > operating Income
-99972
Annuals > 2 > income Statement > interest Expense
-
Annuals > 2 > income Statement > pretax Income
-121506
Annuals > 2 > income Statement > net Income
-121506
Annuals > 2 > income Statement > eps
-0.006094837000003512
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
19935890
Annuals > 2 > income Statement > income Tax Expense
-
Annuals > 2 > income Statement > EBITDA
-109616
Annuals > 2 > income Statement > operating Margin
-
Annuals > 2 > income Statement > total Other Income Expense Net
-21534
Annuals > 2 > income Statement > currency_symbol
USD
Annuals > 2 > balance Sheet > cash
2622279
Annuals > 2 > balance Sheet > short Term Investments
-
Annuals > 2 > balance Sheet > receivables
4814
Annuals > 2 > balance Sheet > inventories
-
Annuals > 2 > balance Sheet > total Current Assets
2785988
Annuals > 2 > balance Sheet > property Plant Equipment
954070
Annuals > 2 > balance Sheet > total Assets
4599977
Annuals > 2 > balance Sheet > payables
632820
Annuals > 2 > balance Sheet > short Term Debt
223520
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
3294389
Annuals > 2 > balance Sheet > equity
1305588
Annuals > 2 > balance Sheet > currency_symbol
USD
Annuals > 2 > cash Flow > net Income
-3732777
Annuals > 2 > cash Flow > depreciation
365231
Annuals > 2 > cash Flow > change In Working Capital
253714
Annuals > 2 > cash Flow > cash From Operations
-2963625
Annuals > 2 > cash Flow > capital Expenditures
212523
Annuals > 2 > cash Flow > cash From Investing
-263009
Annuals > 2 > cash Flow > cash From Financing
458137
Annuals > 2 > cash Flow > net Change In Cash
-2161585
Annuals > 2 > cash Flow > currency_symbol
USD
Annuals > 2 > ratios > PE
-0.006094837000003512
Annuals > 2 > ratios > PB
4.519820525311201
Annuals > 2 > ratios > ROE
-9.30661127400068
Annuals > 2 > ratios > ROA
-2.641447989848645
Annuals > 2 > ratios > FCF
-3176148
Annuals > 2 > ratios > Piotroski FScore
1
Annuals > 2 > ratios > fcf Percent
-
Annuals > 2 > health Score
16
Annuals > 3 > quarter
2022-06-30
Annuals > 3 > income Statement > revenue
0
Annuals > 3 > income Statement > cost Of Revenue
4477
Annuals > 3 > income Statement > gross Profit
-4477
Annuals > 3 > income Statement > operating Expenses
79480
Annuals > 3 > income Statement > operating Income
-83958
Annuals > 3 > income Statement > interest Expense
-
Annuals > 3 > income Statement > pretax Income
-142421
Annuals > 3 > income Statement > net Income
-142421
Annuals > 3 > income Statement > eps
-0.010041080576814503
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
14183832
Annuals > 3 > income Statement > income Tax Expense
-
Annuals > 3 > income Statement > EBITDA
-137943
Annuals > 3 > income Statement > operating Margin
-
Annuals > 3 > income Statement > total Other Income Expense Net
-58462
Annuals > 3 > income Statement > currency_symbol
USD
Annuals > 3 > balance Sheet > cash
4783864
Annuals > 3 > balance Sheet > short Term Investments
-
Annuals > 3 > balance Sheet > receivables
162518
Annuals > 3 > balance Sheet > inventories
-
Annuals > 3 > balance Sheet > total Current Assets
5005711
Annuals > 3 > balance Sheet > property Plant Equipment
1225968
Annuals > 3 > balance Sheet > total Assets
6713499
Annuals > 3 > balance Sheet > payables
762202
Annuals > 3 > balance Sheet > short Term Debt
244636
Annuals > 3 > balance Sheet > long Term Debt
-
Annuals > 3 > balance Sheet > total Liabilities
3221903
Annuals > 3 > balance Sheet > equity
3491596
Annuals > 3 > balance Sheet > currency_symbol
USD
Annuals > 3 > cash Flow > net Income
-4027722
Annuals > 3 > cash Flow > depreciation
126632
Annuals > 3 > cash Flow > change In Working Capital
1504032
Annuals > 3 > cash Flow > cash From Operations
-741450
Annuals > 3 > cash Flow > capital Expenditures
1312130
Annuals > 3 > cash Flow > cash From Investing
-1083684
Annuals > 3 > cash Flow > cash From Financing
6097131
Annuals > 3 > cash Flow > net Change In Cash
4717942
Annuals > 3 > cash Flow > currency_symbol
USD
Annuals > 3 > ratios > PE
-0.010041080576814503
Annuals > 3 > ratios > PB
1.2024341510300733
Annuals > 3 > ratios > ROE
-4.078965607704901
Annuals > 3 > ratios > ROA
-2.121412396129053
Annuals > 3 > ratios > FCF
-2053580
Annuals > 3 > ratios > Piotroski FScore
1
Annuals > 3 > ratios > fcf Percent
-
Annuals > 3 > health Score
31
Valuation > metrics > PE
-0.0005972735674676525
Valuation > metrics > PB
2.1322155809813443
Valuation > final Score
80
Valuation > verdict
Fair
Profitability > metrics > ROE
-0.43024189414285163
Profitability > metrics > ROA
-0.2211619756087002
Profitability > metrics > Net Margin
-0.751453488372093
Profitability > final Score
0
Profitability > verdict
Weak
Risk > metrics > Debt Equity
1.0781332594793025
Risk > metrics > Interest Coverage
-10.939375
Risk > final Score
-14
Risk > verdict
High
Liquidity > metrics > Current Ratio
82.86376848582812
Liquidity > metrics > Quick Ratio
82.73196080933543
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
80
Prev Valuations > 1
20
Prev Valuations > 2
25.878244334128706
Prev Profitabilities > 0
15
Prev Profitabilities > 1
15
Prev Profitabilities > 2
15
Prev Risks > 0
-9
Prev Risks > 1
1
Prev Risks > 2
-14
Prev Liquidities > 0
97
Prev Liquidities > 1
100
Prev Liquidities > 2
91
Updated At
2026-01-20T21:20:09.648Z
Earnings History > 0 > period
2025-09-30
Earnings History > 0 > report Date
2025-10-08
Earnings History > 0 > date
2025-09-30
Earnings History > 0 > before After Market
-
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-0.03
Earnings History > 0 > eps Estimate
-
Earnings History > 0 > eps Difference
0
Earnings History > 0 > surprise Percent
-
Earnings History > 1 > period
2025-06-30
Earnings History > 1 > report Date
2025-06-30
Earnings History > 1 > date
2025-06-30
Earnings History > 1 > before After Market
-
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
-0.0011
Earnings History > 1 > eps Estimate
-
Earnings History > 1 > eps Difference
0
Earnings History > 1 > surprise Percent
-
Earnings History > 2 > period
2025-03-31
Earnings History > 2 > report Date
2025-04-15
Earnings History > 2 > date
2025-03-31
Earnings History > 2 > before After Market
-
Earnings History > 2 > currency
-
Earnings History > 2 > eps Actual
-0.05
Earnings History > 2 > eps Estimate
-
Earnings History > 2 > eps Difference
0
Earnings History > 2 > surprise Percent
-
Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies for precision oncology detection, diagnosis, and treatment in Taiwan. Its devices include A+Pre, an automated sample preparation system that enables pre-concentration of diluted blood samples; AC-1000, a rare cell device to solve the problem of detection of hypercoagulable state samples of tumor patients; A+SCDrop, a circulating tumor cell (CTC) single-cell capture device; and A+CellScan, an analyzer with an immunostaining chip for immunostaining/analysis of the AC-1000 product. The company also offers microfluidic biochips, such as A+Pre, AC-1000 CTC enrichment, and A+CellScan chips to provide assay products and services to cancer patients. In addition, its immunochromogenic kits include A+CTCE kit to identify epithelial circulating tumor cells and determined by the immunochromogenicity of EpCAM, CK (pan), CD45, and CD14 antibodies; A+CTCM kit to identify mesenchymal circulating tumor cells based on the immunochromogenicity of Vimentin, CD45, and CD14 antibodies; A+EMT to identify epithelial-to-mesenchymal circulating tumor cells determined by the immunochromogenicity of cell-surface Vimentin, and CD45 and CD14 antibodies; and A+CM to identify tumor-associated macrophages based on the immunochromogenicity of PD-L1, CD45, and CD14 antibodies. Further, the company is developing A+LCGuard for early screening of lung cancer. Additionally, it establishes and operates medical clinics in the People's Republic of China. The company was founded in 2014 and is headquartered in New York, New York.
Stock Price
$0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AIs ADVB stock positioned well for digital economy - July 2025 News Drivers & Technical Buy Zone Confirmation bollywoodhelpline.com
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Medium
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very Low
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of Advanced Biomed Inc. Common Stock
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
—
EPS Estimate
—
Date
2025-09-30
EPS Actual
-0.03
EPS Estimate
—
EPS Difference
0
Surprise Percent
0%
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.